EGFR-VDR signals in diet-promoted inflammation and cancer
饮食促进的炎症和癌症中的 EGFR-VDR 信号
基本信息
- 批准号:8034800
- 负责人:
- 金额:$ 19.75万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-03-01 至 2012-02-29
- 项目状态:已结题
- 来源:
- 关键词:Animal ModelAnti-Inflammatory AgentsAnti-inflammatoryAzoxymethaneBile AcidsBindingBiologicalBiological AssayCaco-2 CellsCancer EtiologyCell Culture TechniquesCellsCessation of lifeChemopreventive AgentCo-ImmunoprecipitationsColonColon CarcinomaColonic NeoplasmsComplementary DNACytokine SignalingDevelopmentDietDiet ModificationDietary FatsDietary SupplementationDominant-Negative MutationEGF geneEpidermal Growth Factor ReceptorEpidermal Growth Factor Receptor Tyrosine Kinase InhibitorExperimental ModelsFatty acid glycerol estersFibroblastsFoundationsFundingGefitinibGenomicsGoalsGrantGrowthGrowth FactorHalf-LifeHumanIn VitroInflammationInflammation MediatorsInflammatoryKnockout MiceLabelLesionLigandsLinkLithocholic AcidMalignant - descriptorMalignant NeoplasmsMeasuresMediatingMessenger RNAMetabolicModelingMutant Strains MiceOncogenicPathway interactionsPhysiologicalPlayPremalignantProteinsProteomicsReceptor ActivationReceptor Down-RegulationReceptor InhibitionReceptor SignalingRegulationReporterRiskRoleSignal TransductionSmall Interfering RNASolidTimeTranscriptTranscription Factor AP-1Tumor PromotionVitamin DVitamin D AnalogVitamin D3 ReceptorWild Type Mousecancer cellcarcinogenesiscyclooxygenase 2cytokinedietary constituentdietary supplementsin vitro testingin vivoin vivo Modelknock-downpromoterpublic health relevancereceptor expressionresponsetranscription factortumortumorigenesis
项目摘要
DESCRIPTION (provided by applicant): Diet is believed to play a major role in the development of sporadic colon cancer. The azoxymethane (AOM) model of experimental colon cancer mimics many features of human colon cancer, including tumor promotion by Western style high fat diets. Inflammation is thought to contribute to diet-enhanced tumorigenesis. We recently showed that tumor promotion induced by dietary fat required epidermal growth factor receptor (EGFR) signals and involved increased pro-inflammatory cyclooxygenase-2 (Cox-2). In contrast, we demonstrated that dietary supplementation with a vitamin D analogue F6-D3 inhibited inflammation and tumorigenesis. Vitamin D effects are mediated by the vitamin D receptor (VDR). We showed that the VDR could antagonize signals from key inflammatory and oncogenic transcription factors, including NFkB and b-catenin. In recent preliminary studies, we demonstrated that EGFR signals, which are up-regulated in tumorigenesis, suppressed VDR expression. Furthermore, VDR null mice appear to be more susceptible to tumorigenesis. In Aim 1 using the AOM model we will characterize the relationships between diet and EGFR signals and VDR down- regulation and identify VDR pathways that inhibit diet-promoted inflammation and tumorigenesis. We will utilize AOM-treated VDR wild type and VDR null mutant mice to dissect VDR pathways. We will modulate dietary fat to assess the effects of diet on inflammation and tumorigenesis. We will also include a diet supplemented with F6-D3 alone, or F6-D3 plus EGFR inhibitor Gefitinib to dissect VDR and EGFR signals in diet-promoted inflammation and tumorigenesis. We postulate that dietary fat will increase EGFR signals and decrease VDR expression, whereas F6-D3 will increase VDR levels and reduce inflammatory and oncogenic signals and inhibit tumorigenesis. In Aim 2 we will dissect EGFR pathways in colon cancer cells and colonic fibroblasts that down-regulate VDR and uncover VDR mechanisms that oppose EGFR and pro- inflammatory cytokine signals. Caco-2 colon cancer cells and colonic fibroblasts express functional EGFR and VDR. In preliminary studies, EGF down-regulated the VDR in these cells, whereas EGFR inhibition or active vitamin D up-regulated VDR. Thus, EGFR activation in these transformed and non-transformed colonic cells mimics in vitro the effects of EGFR signals on VDR expression in colonic tumorigenesis in vivo. We will uncover the transcriptional and post-transcriptional mechanisms that mediate this VDR down-regulation by EGFR. Potential mechanisms include inhibited promoter activation, and reduced transcript or protein half-life. Using inducible dominant negative EGFR expressing transfectants to control EGFR, and siRNA and cDNA strategies to modulate VDR levels, we will also dissect EGFR and VDR pathways that control inflammation and oncogenesis. Using pathway-specific proteomic and genomic approaches, we will also search for new EGFR and VDR-regulated cytokine and growth factor signals that control inflammation in vitro and test their relevance in our in vivo models. These studies will identify potential new targets to exploit for chemopreventive strategies.
PUBLIC HEALTH RELEVANCE: Colon cancer is the 3rd leading cause of cancer-related deaths in the US. More than half of these malignancies are believed to be preventable by dietary modifications. We have shown that tumor promotion by Western style high fat diets requires epidermal growth factor receptor (EGFR) signals that inhibit anti-inflammatory vitamin D signals. We will uncover EGFR and vitamin D cellular pathways that interact to modulate dietary inflammation and colonic tumor risk.
描述(由申请人提供):饮食被认为在散发性结肠癌的发展中起主要作用。氧化偶氮甲烷(AOM)实验结肠癌模型模拟了人类结肠癌的许多特征,包括西式高脂饮食对肿瘤的促进作用。炎症被认为有助于饮食增强肿瘤发生。我们最近发现,由膳食脂肪诱导的肿瘤促进需要表皮生长因子受体(EGFR)信号,并涉及增加促炎性环氧合酶-2(考克斯-2)。相反,我们证明了膳食补充维生素D类似物F6-D3抑制炎症和肿瘤发生。维生素D的作用由维生素D受体(VDR)介导。我们发现VDR可以拮抗关键炎症和致癌转录因子的信号,包括NF κ B和β-连环蛋白。在最近的初步研究中,我们证明,EGFR信号,这是上调肿瘤发生,抑制VDR的表达。此外,VDR缺失小鼠似乎更容易发生肿瘤。在目标1中,使用AOM模型,我们将表征饮食和EGFR信号与VDR下调之间的关系,并鉴定抑制饮食促进的炎症和肿瘤发生的VDR途径。我们将利用AOM处理的VDR野生型和VDR无效突变小鼠来剖析VDR通路。我们将调节膳食脂肪,以评估饮食对炎症和肿瘤发生的影响。我们还将包括单独补充F6-D3或F6-D3加EGFR抑制剂吉非替尼的饮食,以剖析饮食促进的炎症和肿瘤发生中的VDR和EGFR信号。我们推测,膳食脂肪将增加EGFR信号并降低VDR表达,而F6-D3将增加VDR水平并降低炎症和致癌信号并抑制肿瘤发生。在目标2中,我们将剖析结肠癌细胞和结肠成纤维细胞中下调VDR的EGFR途径,并揭示对抗EGFR和促炎细胞因子信号的VDR机制。Caco-2结肠癌细胞和结肠成纤维细胞表达功能性EGFR和VDR。在初步研究中,EGF下调这些细胞中的VDR,而EGFR抑制或活性维生素D上调VDR。因此,这些转化和非转化结肠细胞中的EGFR活化在体外模拟EGFR信号对体内结肠肿瘤发生中VDR表达的影响。我们将揭示EGFR介导VDR下调的转录和转录后机制。潜在的机制包括抑制启动子激活,和减少转录或蛋白质半衰期。使用可诱导显性阴性EGFR表达转染子来控制EGFR,使用siRNA和cDNA策略来调节VDR水平,我们还将剖析控制炎症和肿瘤发生的EGFR和VDR通路。使用途径特异性蛋白质组学和基因组学方法,我们还将寻找新的EGFR和VDR调节的细胞因子和生长因子信号,这些信号在体外控制炎症,并在我们的体内模型中测试它们的相关性。这些研究将确定潜在的新目标,以利用化学预防策略。
公共卫生相关性:结肠癌是美国癌症相关死亡的第三大原因。这些恶性肿瘤中有一半以上被认为是可以通过饮食调整来预防的。我们已经表明,西式高脂肪饮食促进肿瘤需要表皮生长因子受体(EGFR)信号,抑制抗炎维生素D信号。我们将揭示EGFR和维生素D相互作用调节饮食炎症和结肠肿瘤风险的细胞通路。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Bruce Marc Bissonnette其他文献
Bruce Marc Bissonnette的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Bruce Marc Bissonnette', 18)}}的其他基金
Transfer RNA sequencing and application to cancer research and clinics
将 RNA 测序和应用转移到癌症研究和临床
- 批准号:
10705187 - 财政年份:2022
- 资助金额:
$ 19.75万 - 项目类别:
CXCR4 as a target for colon cancer chemoprevention
CXCR4作为结肠癌化学预防的靶点
- 批准号:
10658900 - 财政年份:2019
- 资助金额:
$ 19.75万 - 项目类别:
CXCR4 as a target for colon cancer chemoprevention
CXCR4作为结肠癌化学预防的靶点
- 批准号:
9803386 - 财政年份:2019
- 资助金额:
$ 19.75万 - 项目类别:
CXCR4 as a target for colon cancer chemoprevention
CXCR4作为结肠癌化学预防的靶点
- 批准号:
10433941 - 财政年份:2019
- 资助金额:
$ 19.75万 - 项目类别:
CXCR4 as a target for colon cancer chemoprevention
CXCR4作为结肠癌化学预防的靶点
- 批准号:
10177972 - 财政年份:2019
- 资助金额:
$ 19.75万 - 项目类别:
Development of 5hmC and 5mC biomarkers in cell-free circulating DNA for sensitive colon cancer detection and prognosis
开发无细胞循环 DNA 中的 5hmC 和 5mC 生物标志物,用于敏感的结肠癌检测和预后
- 批准号:
10220895 - 财政年份:2017
- 资助金额:
$ 19.75万 - 项目类别:
Development of 5hmC and 5mC biomarkers in cell-free circulating DNA for sensitive colon cancer detection and prognosis
开发无细胞循环 DNA 中的 5hmC 和 5mC 生物标志物,用于敏感的结肠癌检测和预后
- 批准号:
9975785 - 财政年份:2017
- 资助金额:
$ 19.75万 - 项目类别:
Development of 5hmC and 5mC biomarkers in cell-free circulating DNA for sensitive colon cancer detection and prognosis
开发无细胞循环 DNA 中的 5hmC 和 5mC 生物标志物,用于敏感的结肠癌检测和预后
- 批准号:
9333644 - 财政年份:2017
- 资助金额:
$ 19.75万 - 项目类别:
Roles of EGFR and miR-143/miR-145 in Western diet-promoted colonic tumorigenesis
EGFR 和 miR-143/miR-145 在西方饮食促进的结肠肿瘤发生中的作用
- 批准号:
8372732 - 财政年份:2012
- 资助金额:
$ 19.75万 - 项目类别:
Roles of EGFR and miR-143/miR-145 in Western diet-promoted colonic tumorigenesis
EGFR 和 miR-143/miR-145 在西方饮食促进的结肠肿瘤发生中的作用
- 批准号:
8854048 - 财政年份:2012
- 资助金额:
$ 19.75万 - 项目类别:
相似海外基金
Development of small molecule inhibitors as anti-inflammatory agents and antidotes for arsenicals
开发作为抗炎剂和砷解毒剂的小分子抑制剂
- 批准号:
10727507 - 财政年份:2023
- 资助金额:
$ 19.75万 - 项目类别:
Discovery of New Anti-Inflammatory Agents to Treat COPD
发现治疗慢性阻塞性肺病的新型抗炎药
- 批准号:
9194162 - 财政年份:2016
- 资助金额:
$ 19.75万 - 项目类别:
Synthesis of anti-inflammatory agents and their structure-activity relationships studies
抗炎药的合成及其构效关系研究
- 批准号:
496858-2016 - 财政年份:2016
- 资助金额:
$ 19.75万 - 项目类别:
University Undergraduate Student Research Awards
NAAA Inhibitors as Anti-inflammatory Agents, Phase II
NAAA 抑制剂作为抗炎剂,II 期
- 批准号:
9201955 - 财政年份:2015
- 资助金额:
$ 19.75万 - 项目类别:
Novel flavonoids as anti-inflammatory agents in alcoholism
新型黄酮类化合物作为酒精中毒的抗炎剂
- 批准号:
8251289 - 财政年份:2014
- 资助金额:
$ 19.75万 - 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
- 批准号:
8302750 - 财政年份:2012
- 资助金额:
$ 19.75万 - 项目类别:
Design and in vivo delivery of novel anti-inflammatory agents
新型抗炎剂的设计和体内递送
- 批准号:
267940 - 财政年份:2012
- 资助金额:
$ 19.75万 - 项目类别:
Operating Grants
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
- 批准号:
8403458 - 财政年份:2012
- 资助金额:
$ 19.75万 - 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
- 批准号:
8472443 - 财政年份:2012
- 资助金额:
$ 19.75万 - 项目类别:
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
- 批准号:
8549297 - 财政年份:2012
- 资助金额:
$ 19.75万 - 项目类别: